Aaron Rosenberg Sells 631 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg sold 631 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $257.74, for a total transaction of $162,633.94. Following the sale, the chief financial officer directly owned 397,891 shares of the company’s stock, valued at $102,552,426.34. The trade was a 0.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 1.6%

NASDAQ:ONC opened at $263.92 on Wednesday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $239.25 and a 52 week high of $385.22. The firm has a 50 day moving average of $297.63 and a 200 day moving average of $313.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $28.96 billion, a price-to-earnings ratio of 59.04 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. As a group, sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Fiera Capital Corp increased its stake in BeOne Medicines by 20.1% during the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock valued at $8,557,000 after purchasing an additional 4,205 shares in the last quarter. BNP Paribas Financial Markets increased its stake in BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after purchasing an additional 97,244 shares in the last quarter. Slow Capital Inc. increased its stake in BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after purchasing an additional 9,280 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in BeOne Medicines during the 3rd quarter valued at approximately $2,726,000. Finally, Capital International Sarl increased its stake in BeOne Medicines by 2.7% during the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ONC shares. Wells Fargo & Company started coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. Wolfe Research started coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Morgan Stanley reissued an “overweight” rating and set a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Finally, Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their price target for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.